Clinical and basic research progress of metformin in improving diabetic retinopathy
10.3760/cma.j.cn115989-20211017-00566
- VernacularTitle:二甲双胍改善糖尿病视网膜病变的临床和基础研究进展
- Author:
Juping LIU
1
;
Xiaorong LI
1
Author Information
1. 天津医科大学眼科医院 天津医科大学眼视光学院 天津医科大学眼科研究所 国家眼耳鼻喉疾病临床医学研究中心天津市分中心 天津市视网膜功能与疾病重点实验室，天津 300384
- Publication Type:Journal Article
- Keywords:
Diabetic retinopathy;
Metformin;
Medication;
AMP-activated protein kinase;
Clinical research;
Basic research
- From:
Chinese Journal of Experimental Ophthalmology
2025;43(8):749-753
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic retinopathy, one of the microvascular complications of diabetes, has become a leading cause of blindness in developed countries.The disease's pathogenesis is complex and involves inflammation and oxidative stress, which eventually lead to retinal microvascular disease and neurodegenerative changes.A large body of clinical and basic research evidence shows that metformin can improve diabetic retinopathy and delay its onset and progression.Metformin exerts protective effects on retinal microangiopathy and retinal cells via AMP-activated protein kinase-dependent and -independent pathways.Metformin can improve retinal cell autophagy, apoptosis and senescence by reducing the oxidative stress response and regulating mitochondrial energy metabolism.Metformin clinical and basic research provides a new approach to treating diabetic retinopathy and a potential direction for developing drugs.This article reviews the progress of clinical and basic research on metformin's protective effects against diabetic retinopathy.
